FDA approves Skyrizi for moderately to severely active Crohn disease
Skyrizi (risankizumab-rzaa), an interleukin-23 inhibitor, has received U.S. Food and Drug Administration approval to treat moderately to severely active Crohn disease (CD) in adults, according to AbbV
Updated on: February 19,2024
15

FDA approves Skyrizi for moderately to severely active Crohn disease
Skyrizi (risankizumab-rzaa), an interleukin-23 inhibitor, has received U.S. Food and Drug Administration approval to treat moderately to severely active Crohn disease (CD) in adults, according to AbbV
Updated on:February 19,2024
15
